Aims
To investigate whether myocardial contrast echocardiography using Sonazoid could be used for the serial evaluation of the presence and extent of myocardial perfusion defects in patients with a first acute myocardial infarction treated with primary PTCA, and specifically, (1) to evaluate safety and efficacy of myocardial contrast echocardiography to detect TIMI flow grade 0-2, (2) to evaluate the success of reperfusion and (3) to predict left ventricular recovery after 4 weeks follow-up.
Methods and Results
Fifty-nine patients underwent serial myocardial contrast echocardiography, immediately before primary PTCA (MCE1), 1 h (MCE2) and 12-24 h after PTCA (MCE3). A perfusion defect was observed in 21 of 24 patients (88%) with anterior acute myocardial infarction. All but one had TIMI flow grade 0-2 prior to PTCA. Nine of 31 patients (29%) with inferior acute myocardial infarction showed a perfusion defect and all had TIMI flow grade 0-2 prior to PTCA. Restoration of TIMI flow grade 3 was achieved in 73% of the patients by primary PTCA. A reduction in size of the initial perfusion defect of at least one segment (16 segment model) or no defect vs persistent defect in patients with anterior acute myocardial infarction was associated with improved global left ventricular function at 4 weeks; mean global wall motion score index 1·29 0·21 vs 1·66 0·31 (P=0·009). Multiple regression analysis in patients with an anterior acute myocardial infarction revealed that the extent of the perfusion defect at MCE3 was a significant (P=0·0005) independent predictor for left ventricular recovery at 4 weeks follow-up. The only other independent predictor was TIMI flow grade 3 post PTCA (P=0·007).
Introduction
Two-dimensional (2D) echocardiography is commonly used to risk stratify patients after acute myocardial infarction [1] [2] [3] [4] . Its availability at the bedside allows rapid evaluation of global and regional ventricular function in the emergency room or coronary care unit [4] . Thus far, its widespread clinical application has been restricted to assessment of myocardial contractile function because no data with regards to myocardial perfusion could be obtained. However, recent advances in ultrasound contrast agents, e.g. improved stability and ability to pass the pulmonary circulation, as well as major developments in ultrasound technology, e.g. harmonic and intermittent imaging, gave myocardial perfusion imaging access, via the intravenous route, to the clinical arena [5, 6] . Myocardial contrast echocardiography following the administration of contrast agents into the coronary arteries can provide important diagnostic information on myocardial perfusion in experimental animals and in patients with acute myocardial infarction in the infarct-related territory, regarding infarct size, myocardial viability, collateral circulation and success of reperfusion [7] [8] [9] [10] [11] [12] [13] . In a recent study, feasibility of the new generation intravenous ultrasound contrast agent Sonazoid (NC100100) has been documented. It demonstrated myocardial contrast enhancement in all patients with chronic myocardial infarction, but provided disappointing results in the assessment of perfusion defects [14] . Therefore, a study was conducted to evaluate the presence of perfusion defects in the no-flow state of acute coronary occlusion with relatively little or insufficient collateral circulation.
The present phase 2 study is the first large multicentre study in patients with a first acute myocardial infarction allocated for primary PTCA using serial intravenous myocardial contrast echocardiography examinations before and after PTCA. Its primary aim was to prospectively evaluate the safety and efficacy of intravenous myocardial contrast echocardiography, using the new ultrasound contrast agent Sonazoid for the detection of myocardial perfusion defects in patients with no flow (TIMI flow grade 0) or reduced flow (TIMI flow grade 1-2) in the infarct-related vessel as determined by coronary angiography at hospital admission. Secondary aims were an evaluation of the success of primary PTCA by a reduction in the size of myocardial perfusion defects in patients before and after PTCA; and an evaluation of the ability of myocardial contrast echocardiography to predict functional recovery of regional and global left ventricular function.
Methods

Study population
Between 9 September 1997 and 31 March 1998, 64 consecutive patients with a first acute myocardial infarction admitted within 6 h of onset of chest pain and with an indication for primary PTCA were enrolled at six centres across Europe. Patients fulfilled all three of the following criteria: history of typical chest pain lasting more than 30 min; ST segment elevation of d0·2 mV in two or more contiguous leads; and an indication for primary PTCA according to the hospital's routine.
Clinical exclusion criteria were: pregnant or breastfeeding women; anyone who had received an investigational drug in the 30 days before onset of myocardial infarction; any clinically life threatening condition except the indication for the trial; and previous coronary artery bypass surgery.
The protocol was approved by all institutional review boards and medical ethics committees of each investigational centre, and all patients provided oral and written informed consent.
Echocardiographic procedure
All studies were performed using Hewlett Packard Ultrasound Systems Sonos 2500 or 5500 equipped for harmonic imaging and a 1·8/3·6 MHz transducer. Instrument setting for myocardial contrast echocardiography was optimized in order to have maximum sensitivity and ideal conditions for visual myocardial contrast detection. The recommended dynamic range was in the medium or mid range (45-55 dB); focal zone depth was set at about 2/3 of the image; a linear curve was established for post-processing; gain was adjusted so that myocardial tissue speckle details could be seen on baseline images (this resulted in a homogeneous backscatter grey level throughout the entire wall of the left ventricle, which was not too white or too black); time and lateral gain compensation adjustments were made in order to have a homogeneous myocardial brightness in the baseline image and a mechanical index between 0·3 and 0·9. Thereafter, all settings were kept constant during the acquisition of the images. Baseline fundamental imaging, including two parasternal (long and short-axis) views and three apical (four-chamber, twochamber and long-axis) views were used to evaluate baseline regional and global wall motion score indexes using a 16-segment analysis prior to myocardial contrast echocardiography [15] . Harmonic imaging was started following baseline imaging, beginning with the apical view which best visualized the dysfunctional area using either the four-or two-chamber view. ECG-triggering (1:1) was done in late end-systole at every heart beat, with image acquisition at the T-wave of the ECG signal, or if this was not well defined, the delay was adjusted to coincide with aortic valve closure or minimum left ventricular size (MCE1). Fundamental 2D echocardiography and myocardial contrast echocardiography were repeated within 1 h (MCE2) and 12-24 h (MCE3) after primary PTCA. Finally, 2D echocardiography was performed 4 weeks after acute myocardial infarction to assess the regional and global wall motion score and ejection fraction, using the area length method from apical four-and two-chamber views.
Echocardiographic contrast agents
After pre-injection recordings, the ultrasound contrast agent Sonazoid was injected intravenously. This contrast agent consists of perfluorocarbon-filled microbubbles with a median diameter of 3-4 m (Nycomed Imaging, Oslo, Norway). The dose of 0·03 l particles . kg 1 body weight of Sonazoid was chosen following results from pilot studies and after each injection 10 ml saline was flushed through [14, 16] . One bolus injection was administered for each echocardiographic view. At least 5 to10 beats prior to and a minimum of 30 beats after the injection were recorded for each view and stored on a magneto-optical disk.
Definitions
The 16-segment model was also used to evaluate the size of the myocardial perfusion defects [15] . Myocardial perfusion of each segment was scored using the following grading: poor or no opacification; adequate opacification or not diagnostic due to technical problems, attenuation or other artifacts. Adequate opacification was scored when the segment showed homogeneous opacification in at least one view and was defined as a change from baseline (5 to 10 consecutive frames) providing there was increased echogenicity or when the appearance of rapid speckle variability became visible. Delayed, poor or no opacification was scored as inadequate myocardial enhancement in any view relative to adjacent segments with adequate opacification. Artifacts were differentiated from perfusion defects prior to final analysis, and segments were judged in terms of their attenuation, poor window, contrast destruction and other artifacts. Wall motion could be interpreted, and a perfusion defect was excluded in a normal contracting segment. Based on MCE1 (before PTCA), the patients were categorized according to the presence or absence of an initial myocardial perfusion defect in at least one segment in the dysfunctional area. The presence of myocardial perfusion in a segment was defined as adequate opacification in that segment in any of the recorded frames. Areas of delayed, no or poor myocardial opacification with absent or non-homogeneous and inadequate myocardial enhancement were regarded as myocardial perfusion defects, in contrast to adjacent segments with adequate opacification. Reflow was defined as a reduction in size of the initial myocardial perfusion defect in at least one segment, as compared to MCE1. No reduction in size or an increase in size of the myocardial perfusion defect on a segmental level was considered as no-reflow.
Coronary angiography
Coronary angiography, and if indicated a primary PTCA, was performed according to the participating centre's policy. Baseline coronary angiograms were digitally recorded to assess TIMI flow grade before passage of the guidewire. The coronary angiograms before and after primary PTCA were sent to the core laboratory at Pisa, Italy for blind review. Angiographic assessments were made by two experienced angiographers without knowledge of the echocardiographic data and clinical outcome. Analysis of coronary angiograms, before and after PTCA, was performed for lesion localization and assessment of flow in the infarct-related vessel, using the classification of the Thrombolysis in Myocardial Infarction trial (TIMI) before and after completion of the primary PTCA, and this was considered the primary variable of the study [17] .
Electrocardiograms
Standard 12-lead electrocardiograms (ECG) were obtained from all patients at baseline; immediately after MCE2 and MCE3; at 1 h, 2 h and 4 h after PTCA, respectively. The ST segment was evaluated 60 ms after the J-point in each lead. The sum of ST elevation in all 12 leads was measured.
Data analysis
All echocardiographic data were downloaded and stored digitally in a full cineloop (for wall motion) or loops with triggered images (for myocardial contrast echocardiography) on magneto-optical disc and sent to the central core-laboratory for subsequent editing and blinded review. Editing was necessary to delete all identification markers, such as the name of the centre and patient identification. The review was done by two investigators, one reviewing all data, the other 30% of the data. Two different modes of 'blind read' were performed; in the first blind read (read 1) all single views of wall motion, as well as all triggered cineloops with myocardial contrast echocardiography examinations, were randomized, without side-by-side evaluation, thus without wall motion information at the time of myocardial contrast echocardiography reading. In the second blind read (read 2), corresponding wall motion and myocardial contrast echocardiography images were viewed in a side-by-side display (Hewlett Packard, EnConcert), thus myocardial contrast echocardiography was evaluated together with wall motion data in a randomized order.
Intra-and inter-observer variability
Intra-observer variability of myocardial contrast echocardiography was determined by one observer making duplicate observations (read 1 compared with read 2), inter-observer variability was determined by a second observer analysing 30% of the images (read 1).
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Both observers were blinded to patient data and the results of the other observer.
Statistical analysis
Baseline descriptive data are presented in numbers, percentages or mean SD. Patients were divided into two groups: patients with a reduction (d1 segment) in the extent of the perfusion defect, or no defect (the reflow group) and patients showing no reduction in the extent of the perfusion defect by serial myocardial contrast echocardiography (no-reflow group). Group differences in clinical, electrocardiographic, echocardiographic and angiographic variables were assessed by two-tailed Student's t-test, Wilcoxon rank sum test, or by Chi-square analysis for proportion, or Fisher's exact test. Variables that showed a significant correlation with left ventricular function at 4 weeks (global wall motion score index) were submitted to univariate regression analysis and multiple regression analysis to determine independent correlates. A P-value <0·05 was considered statistically significant.
Results
Patient characteristics
A total of 64 consecutive patients were included, of whom 59 were available for the main end-point defined as TIMI flow grading by coronary angiography prior to primary PTCA. Five patients did not undergo myocardial contrast echocardiography study because of early mortality (n=2; both patients had irreversible cardiogenic shock), poor acoustic window (n=1) or inclusion criteria not fulfilled (n=2). From the serial myocardial contrast echocardiography studies, the first was adequately performed in 55 patients (93%), the second in 52 patients (88%) and the third in 53 patients (90%). Complete datasets including MCE1, MCE2 and MCE3, coronary angiography before and after primary PTCA, were obtained in 49 patients (83%) of the present study. Left ventricular function at 4 weeks follow-up, the secondary end-point, was obtained in 47 patients (80%), see also 
Safety and clinical events
During the follow-up period of 4 weeks, five patients (8%) died due to infarct-related complications and none of the deaths were related to the ultrasound contrast agent, as estimated by the investigators.
One patient had a recurrent myocardial infarction and another had coronary artery bypass surgery during the 4 weeks of follow-up. During hospitalization, six patients had life-threatening ventricular arrhythmias, mostly ventricular fibrillation. None of the adverse events were considered related to the ultrasound contrast agent, although two adverse events were classified as having an uncertain relation to the ultrasound agent -one patient with renal insufficiency and another with ventricular tachycardia. No significant changes were observed in heart rate and blood pressure before or after the myocardial contrast echocardiography studies.
Feasibility and efficacy
Evaluation of myocardial perfusion defects was feasible in 50 of 55 patients (91%) at MCE1, 44 of 52 patients at MCE2 (85%) and 47 of 53 patients (89%) at MCE3. In patients with anterior acute myocardial infarction, diagnosis was feasible in 24 of 24 patients (100%) at MCE1, 22 of 23 patients (96%) at MCE2 and 23 of 23 patients (100%) at MCE3. In patients with inferior acute myocardial infarction, feasibility for assessing myocardial perfusion defects was lower; 26 of 31 patients (84%), 22 of 29 patients (76%) and 25 of 30 patients (83%), respectively.
In patients with an anterior acute myocardial infarction, a perfusion defect was present in 21 of 24 patients (88%) at MCE1, in 19 of 23 patients (83%) at MCE2 and in 19 of 23 patients (83%) at MCE3. In patients with an inferior acute myocardial infarction, perfusion defects were observed in 9 of 31 patients (29%), 2 of 29 patients (7%) and 6 of 30 patients (20%), respectively. Considering all patients, irrespective of infarct location, the presence of a myocardial perfusion defect in patients with a first acute myocardial infarction had a predictive value of 59% (95% CI from 41 to 76%) for TIMI flow grade 0 before primary PTCA (Table 1) . Efficacy data for the presence or absence of a myocardial perfusion defect at MCE1 for prediction of TIMI flow grading prior to PTCA are provided in Table 2 .
Evaluation of reperfusion after primary PTCA
Clinical and angiographic variables in patients with a reduction of defects or no defect vs persistent defects are listed in Table 3 . More anterior infarcts (P=0·002) were found, and consequently, the infarct-related vessel was more often the left anterior descending (P=0·006) and less frequently the right coronary artery (P=0·005) in patients with a persistent perfusion defect. 
Prediction of left ventricular function and recovery at 4 weeks
Patency of the infarct-related vessel before PTCA (P=0·05) and the success of primary PTCA defined by TIMI flow grade 3 (P=0·003) or TIMI flow grades 2 and 3 (P=0·02) and time from inclusion to reperfusion (P=0·02) were all significantly associated with global wall motion score index <1·5 at 4 weeks follow-up, and thus functional recovery (Table 4 ). Table 5 shows the impact of myocardial contrast echocardiography in predicting global left ventricular function at 4 weeks follow-up. In patients with an anterior acute myocardial infarction, the extent of the perfusion defect at MCE2 and MCE3 best predicts lack of recovery of global ventricular function, as indicated by global wall motion score index d1·5 at 4 weeks (P<0·001). On the other hand, in patients with an inferior acute myocardial infarction, wall motion score index, especially between 12-24 h, but not perfusion defects detected by myocardial contrast echocardiography, predict functional recovery. In the reduction group, 7 out of 8 patients with an anterior acute myocardial infarction had functional recovery compared to 2 of 11 patients without a reduction (P<0·01). In inferior infarcts, the proportion of patients without a reduction was too small. The sum of ST segment elevation in the 12-lead ECG was insufficient to predict recovery of left ventricular function (P=ns).
On the other hand, in non-perfused segments of the infarct-related vessel, the size of the defect in the dysfunctional zone was related to poor global function, as indicated by the global wall motion score at 4 weeks (R 2 =0·41). Multiple regression analysis, in patients with an anterior acute myocardial infarction, revealed that the extent of the perfusion defect at MCE3 was a significant (P=0·0005) independent predictor of left ventricular 
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recovery at 4 weeks follow-up. The only other independent predictor was TIMI flow grade 3 post PTCA (P=0·007).
Intra-and inter-observer variability
Intra-reader variability on a segment level for MCE1 had an agreement of 92% and of 0·82 for patients with an anterior infarction, and an agreement of 91% and of 0·34 for patients with an inferior infarction. Interreader variability had an agreement of 78% and of 0·48 for patients with an anterior infarction vs agreement of 81% and of 0·16 for patients with an inferior infarction. Numbers were comparable for subsequent echocardiograms and did not change over time.
Discussion
The important finding in this multicentre study is that 2D echocardiography, in combination with the new generation intravenous ultrasound contrast agent Sonazoid , is safe and allows serial myocardial perfusion imaging in patients presenting with a first acute myocardial infarction. This allows non-invasive and immediate evaluation of an occluded infarct-related vessel, as well as assessment of success of reperfusion therapy, particularly in patients with an anterior acute myocardial infarction. The presence and extent of the perfusion defect carries important prognostic information with regard to subsequent left ventricular function at 4 weeks. The current study is the first in which myocardial perfusion was evaluated serially in consecutive patients using an intravenous ultrasound contrast agent in the emergency room or the coronary care unit.
Safety of intravenous myocardial contrast echocardiography in acute myocardial infarction
Seven patients died after inclusion in the present study, two patients before the first ultrasound contrast injection. The mortality rate reflects the high-risk study population and hospital selection, with a substantial number of patients admitted from referral hospitals for primary PTCA. Mortality rates of experienced centres treating patients with primary PTCA for acute myocardial infarction range from 2·6% to 14·2% and can be explained by differences in patient selection [18] . All causes of death in our study were infarct-related and none was related to the ultrasound contrast agent or any in-hospital delay due to the myocardial contrast echocardiography. 
Detection of myocardial contrast defects in patients with total occlusion of the infarct-related vessel
At present, most clinical trials in patients with acute myocardial infarction have focused on restoring the patency of the infarct-related vessel [19] [20] [21] [22] [23] [24] [25] [26] . Our data show that sensitivity of intravenous myocardial contrast echocardiography to detect perfusion defects in patients with an anterior acute myocardial infarction, with documented total occlusion of the culprit artery, is excellent. Also, information on myocardial microvascular perfusion is an important diagnostic issue, over and above 3 (13%) 6 (25%) 0·25 Anterior infarct, n (%) 10 (43%) 11 (46%) 0·87 Inferior/posterior infarct, n (%) 13 (57%) 13 (54%) 0·87 IRV: left anterior descending, n (%) 10 (45%) 13 (54%) 0·56 IRV: right coronary artery, n (%)
15 ( 
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segmental wall motion abnormalities in patients with an acute myocardial infarction. Potentially, the immediate bedside evaluation of myocardial perfusion by myocardial contrast echocardiography in patients with an acute myocardial infarction might guide our therapeutic strategies in the near future, because myocardial contrast echocardiography is helpful in differentiating perfused or stunned myocardium from non-perfused myocardium in the presence of wall motion abnormalities [27, 28] . Wall motion abnormalities are observed in transient or chronic myocardial ischaemia as well as scar tissue. Therefore, perfusion information, in addition to functional information, is the required imaging approach for more accurate diagnosis and work-up of patients with acute ischaemic syndromes. Lack of myocardial contrast enhancement in dysfunctional segments allows evaluation of non-perfused regions in the dyssynergic myocardium. In this way, the presence of a perfusion defect in a patient with a first acute myocardial infarction was capable of predicting TIMI flow grade 0 with a high sensitivity, especially in patients with a first anterior acute myocardial infarction.
Assessment of myocardial perfusion following primary PTCA
Reperfusion therapy with intravenous thrombolytic agents or primary PTCA has emerged in the past decade as an effective means of reducing infarct size, preserving ventricular function and morphology, reducing electrical instability, and reducing morbidity and mortality in patients with an acute evolving myocardial infarction [23] [24] [25] [26] . However, increasing evidence exists that mortality and morbidity after acute myocardial infarction is related to microvascular integrity rather than to restored infarct-related vessel patency alone [13] . Restoring the patency of the infarct-related vessel has become the standard goal in patients with acute myocardial infarction. However, approximately one third of patients with a patent infarct-related vessel defined by TIMI flow grade 3, exhibit damage to the microvascular bed, and this loss of microvascular integrity is related to infarct size and morbidity [9, 19] . The ultimate goal of reperfusion therapy is to obtain microvascular salvage, which is a prerequisite for viability and functional recovery [28] . Re-establishment of the culprit artery patency (TIMI flow grade 3) was obtained in 73% of the patients in the present study. However, even with restoration of epicardial coronary blood flow, reperfusion at the level of myocardial tissue may fail to occur due to the no-reflow phenomenon consecutive to extensive myocardial cell necrosis and microvascular damage. In patients with an anterior acute myocardial infarction, we were able to demonstrate that microvascular integrity assessed by myocardial contrast echocardiography was a better predictor of functional outcome beyond coronary artery patency.
It was evident from serial myocardial contrast echocardiography examinations that most patients had a perfusion defect prior to, but also after, successful primary PTCA. Approximately one third of the patients had a reduction in size of the myocardial perfusion defect, indicating that more perfusion defects are observed after patency has been restored compared to previous intracoronary studies [22] . A potential explanation can be the lower detection rate in intermediate or low perfusion areas using an intravenous contrast agent. On the other hand, the no-reflow phenomenon might be redefined for the use of an intravenous contrast agent, because non-physiological high pressure perfusion is avoided, as present for intracoronary injections. Currently, the assessment of whether or not reperfusion therapy is successful is based on clinical symptoms and ECG, and only a few hospitals perform scintigraphic imaging. The ECG may not be the ideal test to detect failure of reperfusion because of lack of sensitivity, and logistic as well as financial aspects limit the use of scintigraphy in daily practice. A quick, reliable and inexpensive test that can be repeated serially would be of great value for the selection of those patients who need further invasive examinations.
Prediction of left ventricular function 1 month after acute myocardial infarction
Using serial myocardial contrast echocardiography in patients with an anterior acute myocardial infarction, dynamic changes in the perfusion defect, defined as a reduction in size or no perfusion defect (reflow), predicts better functional recovery compared to patients with no-reflow. Delineation of the true infarct size would be more accurate, especially after the hyperaemic phase of acute myocardial infarction (MCE3), and infarct location may be determined, as well as the region of microvascular integrity, all important information for risk stratification of patients with an acute myocardial infarction and their further functional recovery after primary PTCA. Inadequate reperfusion for technical reasons, poor distal run-off, or the presence of abnormal microvasculature within the revascularized bed, all influence viability and thus recovery of function. Recent studies have shown that microvascular integrity is closely associated with myocardial cellular viability after acute myocardial infarction in patients [28] . Myocardial contrast echocardiography may therefore provide early additional information incremental to wall motion, regarding functional recovery and viability after reperfusion, as demonstrated in our study. Probably due to better preservation of regional and global function in patients with inferior infarcts, and the relatively low proportion of patients without a reduction of the initial perfusion defect, we were unable to demonstrate an effect on functional recovery in these patients. Furthermore, we showed a lack of sensitivity by the 12-lead ECG in predicting recovery of left ventricular function. This might be explained by the limited analysis of the 12-lead ECG, using the sum of ST elevation in all 12-leads only and not ST elevation and changes within a single lead.
Limitations
At present, there are several limitations for the widespread clinical application of intravenous myocardial contrast echocardiography in the evaluation of perfusion abnormalities in patients with acute myocardial
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infarction. Although there is no evidence in earlier experimental animal studies (unpublished data) or in the present study with acute coronary occlusion, that the contrast agent is of any harm to the patient with acute myocardial infarction, the proportion of patients with TIMI flow grade 3 after primary PTCA is relatively low, and this might raise some concerns about side-effects within the microcirculation. Also, despite an increasing understanding with regard to interaction of the microbubbles, the ultrasound beam and the optimal machine settings, especially with the present agent Sonazoid , a significant proportion of the segments could not be analysed and were considered as non-diagnostic, especially in the inferior and lateral walls. With recent technical developments, the myocardial signal could be further enhanced, albeit that attenuation and lateral resolution problems will remain important limitations [6, 29] . Microbubble destruction in the high energy near field of the ultrasound beam could explain the high proportion of perfusion defects in the apical region. However, our data show that the vast majority of segments with perfusion defects in the apical region do not recover function at follow-up and most apical defects were asymmetrical in shape. Therefore, it is unlikely that these are artifacts, they represent true perfusion defects.
Myocardial perfusion is not necessarily homogeneous and normal variations occur. Thus, opacification of segments was judged relative to their baseline grey levels and despite the subjective nature of the analysis, the well-trained readers had good intra-and inter-reader agreement.
A dedicated education and training programme prior to the start of the study was provided in all participating centres and almost all centres participated in a previous trial with Sonazoid in patients with chronic myocardial infarction [14] . However, to perform myocardial contrast echocardiography studies in acutely ill patients in the emergency department or coronary care unit is demanding and a well organized infrastructure with up-to-date ultrasound equipment and expert sonographers are crucial.
Conclusion
Intravenous contrast with Sonazoid is safe, feasible and allows evaluation of myocardial perfusion and perfusion defects in patients with a first acute myocardial infarction and predicts angiographically total infarct-related vessel occlusion with a high sensitivity particularly in anterior acute myocardial infarction. Improvement of the initial myocardial perfusion defect was correlated with a better left ventricular function at 4 weeks in patients with anterior acute myocardial infarction. This suggests that serial intravenous myocardial contrast echocardiography is a valuable diagnostic and prognostic imaging technique in patients with a first acute myocardial infarction. Thus, intravenous myocardial contrast echocardiography in the setting of acute myocardial infarction and primary PTCA provides clinically relevant information although this needs to be confirmed in larger trials, especially in patients with acute myocardial infarction receiving thrombolysis.
